MNPR Healthcare

Monopar Therapeutics Inc.

$69.89+5.45%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 469.1M USD
Enterprise value: 335.0M USD
Full-time employees: 22

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.50 vs a peer median of 0.63)bigger price swings (beta 1.50 vs peers 0.63)
Not enough data: growth

Would rank #625 of 1,157 fully scored healthcare companies (bottom 47%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 159% from December 2022 to July 2026.
Monopar Therapeutics had 159% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Monopar Therapeutics had 159% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Monopar Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Monopar Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
Monopar Therapeutics has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

50/ 100

Oct 5 50 → Nov 4 50

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-3.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-2.6%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield27.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

23/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-13.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.77Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-22.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.70Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-13.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.50

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.58Sector median: 0.6250 · MAD: 0.3380

Current ratio33.56×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Monopar Therapeutics

Is Monopar Therapeutics getting weaker?: Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.
How is Monopar Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -3.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.8% vs peers 1.5% (weaker than 100% of peers).
Is Monopar Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Monopar Therapeutics?: Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -22.4% vs a peer median of 4.7% (weaker than 80% of peers).Return on invested capital -22.4% vs peers 4.7% (weaker than 80% of peers).
How risky is Monopar Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 33.56× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 33.56× vs peers 2.59× (stronger than 95% of peers). Beta 1.50 vs a peer median of 0.63 (weaker than 87% of peers).Beta 1.50 vs peers 0.63 (weaker than 87% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Aug 12, 2026 · compared with the quarter ended Sep 30, 2025

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−19.4M USD	−17.8M USD	−8.2%
Cash	127.7M USD	52.8M USD	−58.7%
Shares outstanding	6.7M	6.7M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-44.4%	-79.5%	-114.4%	-25.9%	-9.7%	▲ 16 pts
Return on equity (ROE)	-48.1%	-104.2%	-150.4%	-28.3%	-10.0%	▲ 18 pts
Current ratio	12.98×	4.21×	4.17×	11.47×	51.35×	▲ 348%

MNPR price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.50 vs a peer median of 0.63)bigger price swings (beta 1.50 vs peers 0.63)

Not enough data: growth

Would rank #625 of 1,157 fully scored healthcare companies (bottom 47%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 159% from December 2022 to July 2026.

Monopar Therapeutics had 159% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Monopar Therapeutics had 159% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Monopar Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Monopar Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

Monopar Therapeutics has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about Monopar Therapeutics

Is Monopar Therapeutics getting weaker?

Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.

How is Monopar Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -3.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.8% vs peers 1.5% (weaker than 100% of peers).

Is Monopar Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Monopar Therapeutics?

Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -22.4% vs a peer median of 4.7% (weaker than 80% of peers).Return on invested capital -22.4% vs peers 4.7% (weaker than 80% of peers).

How risky is Monopar Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 33.56× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 33.56× vs peers 2.59× (stronger than 95% of peers). Beta 1.50 vs a peer median of 0.63 (weaker than 87% of peers).Beta 1.50 vs peers 0.63 (weaker than 87% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−19.4M USD

−17.8M USD

−8.2%

Cash

127.7M USD

52.8M USD

−58.7%

Shares outstanding

6.7M

6.7M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-44.4%

-79.5%

-114.4%

-25.9%

-9.7%

▲ 16 pts

Return on equity (ROE)

-48.1%

-104.2%

-150.4%

-28.3%

-10.0%

▲ 18 pts

Current ratio

12.98×

4.21×

4.17×

11.47×

51.35×

▲ 348%